Rifampicin-loaded 'flower-like' polymeric micelles for enhanced oral bioavailability in an extemporaneous liquid fixed-dose combination with isoniazid

Nanomedicine

Volumn 9, Issue 11, 2014, Pages 1635-1650

  Moretton, Marcela A ^a,b   Hocht, Christian ^a   Taira, Carlos ^a,b   Sosnik, Alejandro ^a,b,c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b National Science Research Council   (Argentina)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

extemporaneous liquid rifampicin isoniazid fixed dose combination; improved oral pharmacokinetics; pediatric tuberculosis; poly( caprolactone) b PEG b poly( caprolactone) 'flower like' polymeric micelle; rifampicin chemical stabilization

Indexed keywords

ISONIAZID PLUS RIFAMPICIN; POLYMER; DRUG CARRIER; ETHYLENE GLYCOL DERIVATIVE; HYDROCHLORIC ACID; ISONIAZID; LACTIDE-CAPROLACTONE COPOLYMER; MICELLE; POLY(EPSILON-CAPROLACTONE)-B-POLY(ETHYLENE GLYCOL); POLYESTER; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG STABILITY; IN VITRO STUDY; MEDICAL LITERATURE; MICELLE; NANOENCAPSULATION; PEDIATRICS; UNITED STATES; ANIMAL; AREA UNDER THE CURVE; BIOAVAILABILITY; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NANOMEDICINE; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; RAT; SOLUBILITY; TUBERCULOSIS; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; ETHYLENE GLYCOLS; HYDROCHLORIC ACID; ISONIAZID; MALE; MICELLES; NANOMEDICINE; PARTICLE SIZE; POLYESTERS; POLYMERS; RATS; RATS, WISTAR; RIFAMPIN; SOLUBILITY; TUBERCULOSIS;

EID: 84902343814     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.154     Document Type: Article

References (55)

1. Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat. Med. 11, S33-S44 (2005).
2. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 362, 887-899 (2003).
3. Sharma S, Sharma PK, Kumar N, Dudhe R. A review on various heterocyclic moieties and their antitubercular activity. Biomed. Pharmacother. 65, 244-251 (2011).
4. Bertel Squire S, Thomson S. Tuberculosis and poverty. In: Tuberculosis-A Comprehensive Clinical Reference. Schaaf SH, Zumla AL, Grange JM et al. (Eds). Saunders Elsevier, London, UK (2009).
5. WHO declares tuberculosis a global emergency. Soc. Prevent. Med. 38, 251-252 (1993).
6. Rivers EC, Mancera RL. New antituberculosis drugs in clinical trials with novel mechanism of action. Drug Discov. Today 13, 1090-1098 (2008).
7. Matteelli A, Carvalho A, Dooley KE, Kritski A. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 5, 849-858 (2010).
8. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998).
9. Singh S, Mariappan TT, Sharda N, Kumar S, Chakrabarti AK. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions. Pharm. Pharmacol. Commun. 6, 405-410 (2000).
10. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Kotecha JS, Shah PB. Stability of rifampicin in dissolution medium in presence of isoniazid. Int. J. Pharm. 190, 109-123 (1999).
11. Sankar R, Sharda N, Singh S. Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3. Drug Dev. Ind. Pharm. 29, 733-738 (2003).
12. Shishoo CJ, Shah SA, Rathod IS, Savale SS. Impaired bioavailability of rifampicin from fixed dose combination (FDC) formulations with isoniazid. Indian J. Pharm. Sci. 63, 443-449 (2001).
13. Singh S, Mariappan TT, Sankar R, Sarda N, Singh B. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combinations (FDC) products, and the likely solutions to the problem. Int. J. Pharm. 228, 5-17 (2001).
14. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull. World Health Organ. 79, 61-68 (2001).
15. Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin. Infect. Dis. 50, S184-S194 (2010).
16. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359, 2188-2194 (2002).
17. Sosnik A, Seremeta KP, Imperiale JC, Chiappetta DA. Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases (PRDs). Expert Opin. Drug Deliv. 9, 303-323 (2012).
18. Sosnik A, Carcaboso AM, Glisoni RJ, Moretton MA, Chiappetta DA. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv. Drug Del. Rev. 62, 547-559 (2010).
19. Choonara YE, Pillay V, Ndesendo VM et al. Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers. Colloids Surf. B Biointerfaces 87, 243-254 (2011).
20. Sosnik A, Carcaboso A, Chiappetta DA. Polymeric nanocarriers: new endeavors for the optimization of the technological aspects of drugs. Recent Pat. Biomed. Eng. 1, 43-59 (2008).
21. Chiappetta DA, Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. Eur. J. Pharm. Biopharm. 66, 303-317 (2007).
22. Chiappetta DA, Hocht C, Taira C, Sosnik A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailaibility. Nanomedicine (Lond.) 5, 11-23 (2010).
23. Chiappetta DA, Hocht C, Taira C, Sosnik A. Oral pharmacokinetics of efavirenz-loaded polymeric micelles. Biomaterials 32, 2379-2387 (2011).
24. Peroni RN, Di Gennaro SS, Hocht C et al. Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat. Biochem. Pharmacol. 82, 1227-1233 (2011).
25. Chiappetta DA, Hocht C, Opezzo JA, Sosnik A. Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Nanomedicine (Lond.) 8, 223-237 (2013).
26. Ribeiro A, Sosnik A, Chiappetta DA, Veiga F, Concheiro A, Alvarez-Lorenzo C. Single and mixed poloxamine micelles as suitable nanocarriers for solubilization and sustained release of ethoxzolamide for topical glaucoma therapy. J. R. Soc. Interface 9, 2059-2069 (2012).
27. Moretton MA, Glisoni RJ, Chiappetta DA, Sosnik A. Molecular implications in the nanoencapsulation of the antituberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf. B Biointerfaces 79, 467-479 (2010).
28. Moretton MA, Chiappetta DA, Sosnik A. Cryoprotection-lyophilization and physical stabilization of rifampicin loaded flower-like polymeric micelles. J. R. Soc. Interface 9, 487-502 (2012).
29. Gotelli G, Bonelli P, Abraham G, Sosnik A. Fast and efficient synthesis of high molecular weight poly(e-caprolactone) diols by microwave-assisted polymer synthesis (MAPS). J. Appl. Polym. Sci. 121, 1321-1329 (2011).
30. Sosnik A, Gotelli G, Abraham GA. Microwave-assisted polymer synthesis (MAPS) as a tool in biomaterials science: how new and how powerful. Prog. Polym. Sci. 36, 1050-1078 (2011).
31. Sreenivasa Rao B, Ramana Murthy KV. Studies on rifampicin release from ethylcellulose coated nonpareil beads. Int. J. Pharm. 231, 97-106 (2002).
32. Ritger PL, Peppas NA. A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J. Control. Release 5, 23-36 (1987).
33. Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Control. Release 5, 37-42 (1987).
34. Hu Y, Ding Y, Li Y, Jiang X, Yang C, Yang Y. Physical stability and lyophilization of poly(caprolactone)-b-poly(ethyleneglycol)-b-poly(caprolactone) micelles. J. Nanosci. Nanotech. 6, 1-8 (2006).
35. Chiappetta DA, Hocht C, Sosnik A. Highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy. Curr. HIV Res. 8, 223-231 (2010).
36. Moretton MA, Glisoni RJ, Chiappetta DA, Sosnik A. Synthesis and characterization of amphiphilic poly(e-caprolactone)-poly(ethylene glycol) block copolymers. Optimization of the solubility and stability of rifampicin by means of encapsulation into polymeric micelles. Presented at: BIOOMAT 2009, I Workshop on Artificial Organs, Biomaterials and Tissue Engineering. Rosario, Argentina, 25-27 August 2009.
37. Agrawal SK, Sanabria-DeLong N, Coburn JM, Tew GN, Bhatia SR. Novel drug release profiles from micellar solutions of PLA-PEO-PLA triblock copolymers. J. Control. Release 112, 64-71 (2006).
38. Bastakoti BP, Guragain S, Yokoyama Y, Yusa S-I, Nakashima K. Incorporation and release behavior of amitriptylene in core-shell-corona type triblock copolymer micelles. Colloids Surf. B Biointerfaces 88, 734-740 (2011).
39. Lin WJ, Juang LW, Lin CC. Stability and release performance of a series of pegylated copolymeric micelles. Pharm. Res. 20, 668-673 (2003).
40. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13, 123-133 (2001).
41. Wang Q, Zhang J, Wang A. Preparation and characterization of a novel pH-sensitive chitosan-g-poly (acrylic acid)/attapulgite/sodium alginate composite hydrogel bead for controlled release of diclofenac sodium. Carbohyd. Polym. 78, 731-737 (2009).
42. Forrest ML, Won C-Y, Malick WA, Kwon GS. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(-caprolactone) micelles. J. Control. Release 110, 370-377 (2006).
43. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59, 645-666 (2007).
44. Tewes F, Brillault J, Couet W, Olivier J-C. Formulation of rifampicin-cyclodextrin complexes for lung nebulisation. J. Control. Release 129, 93-99 (2008).
45. McConnell EL, Basit AW, Murdan S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in vivo experiments. J. Pharm. Pharmacol. 60, 63-70 (2004).
46. Armijo JA. Absorción, distribución y eliminación de fármacos. In: Farmacología Humana (3rd Edition). Florez J, Armijo JA, Mediavilla A (Eds). Masson, Barcelona, Spain (1997).
47. Loftsson T, Brewster ME. Cyclodextrins as functional excipients: methods to enhance complexation efficiency. J. Pharm. Sci. 101, 3019-3032 (2012).
48. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. J. Pharm. Pharmacol. 63, 1119-1135 (2011).
49. Jansook P, Loftsson T. CDs as solubilizers: effects of excipients and competing drugs. Int. J. Pharm. 379, 32-40 (2009).
50. Jayaram R, Gaonkar S, Kaur P et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47, 2118-2124 (2003).
51. WHO. Global Tuberculosis Report. www.who.int/tb/publications/global-report/2011/gtbr11-full.pdf (Accessed January 2013)
52. WHO. Treatment of tuberculosis: guidelines. http://whqlibdoc.who.int/publications/2010/9789241547833-eng.pdf (Accessed January 2013)
53. WHO. The top ten causes of death. www.who.int/mediacentre/factsheets/fs310/en/index.html (Accessed August 2012)
54. WHO. Dosing instructions for the use of currently available fixed-dose combination TB medicines for children. www.who.int/tb/challenges/interim-paediatric-fdc-dosing-instructions-sept09.pdf (Accessed July 2013)
55. WHO. WHO list of prequalified medicinal products. http://apps.who.int/prequal/query/ProductRegistry.aspx?list=tb (Accessed March 2013)